ALEXANDRIA, Va. — In a bipartisan effort, Sens. Kent Conrad, D-N.D., and Olympia Snowe, R-Maine, along with 12 of their colleagues, have expressed concerns with draft Federal Upper Limits lists for Medicaid generic drug reimbursement that recently have been published by the Centers for Medicare and Medicaid Services.
The National Association of Chain Drug Stores and National Community Pharmacists Association commended the Senators for the effort.
"In publishing three draft lists of Medicaid drug FULs, CMS has provided states with a potential unofficial standard for setting state maximum allowable costs. Specifically, pharmacists believe that if states were to implement MACs based on the CMS’s draft FUL lists, pharmacies could see reduced reimbursement for selected generic drugs in the range of 30% to 60% of acquisition costs. Cuts of this magnitude could create a disincentive to dispense generic drugs, which is exactly the opposite of what we should be trying to achieve as we seek to control healthcare costs," the senators wrote in a letter to CMS. Fourteen senators signed the letter to CMS.
NACDS and NCPA also have expressed concern with the draft FUL lists in written comments to CMS. “We are pleased that our arguments have been given further credibility by a large, bipartisan group of senators,” stated NACDS president and CEO Steve Anderson and NCPA CEO B. Douglas Hoey. “We want to especially thank senators Conrad and Snowe for their leadership on this important issue.”
In addition to urging CMS to cease publication of draft FUL lists until a final AMP rule is in place, the Senators also urged the agency to be mindful of comprehensive pharmacy reimbursement. “When setting pharmacy reimbursement rates, it is important that both components of reimbursement — product cost and cost to dispense — be taken into consideration to ensure pharmacies are adequately paid,” the senators wrote.
Last month, a similar bipartisan letter was sent to CMS by 40 U.S. representatives raising concerns over the flawed Medicaid pharmacy reimbursement process.